Showing results (31-40 of 42) with videos related to
Sort By:
Pageof 5
American Journal of Hematology|August 23, 2021
Carfilzomib and dexamethasone induction with lenalidomide, clarithromycin and dexamethasone consolidation and lenalidomide maintenance for newly diagnosed multiple myelomaPeter A Forsberg, Adriana C Rossi, Angelique Boyer, et al.Bone Marrow Transplantation|June 14, 2019
High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myelomaAlexandra Gomez-Arteaga, Tomer M Mark, Danielle Guarneri, et al.British Journal of Haematology|February 8, 2021
Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trialVania Hungria, Meral Beksac, Katja C Weisel, et al.American Journal of Hematology|February 12, 2019
Phase II study of carfilzomib and dexamethasone therapy for newly diagnosed multiple myelomaPeter A Forsberg, Adriana C Rossi, Angelique Boyer, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 30, 2013
Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilizationRuben Niesvizky, Tomer M Mark, Maureen Ward, et al.The New England Journal of Medicine|August 25, 2016
Daratumumab, Bortezomib, and Dexamethasone for Multiple MyelomaAntonio Palumbo, Asher Chanan-Khan, Katja Weisel, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2022
Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III TrialPieter Sonneveld, Asher Chanan-Khan, Katja Weisel, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 29, 2017
Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse SurvivalMyo Htut, Anita D'Souza, Amrita Krishnan, et al.Cancer|May 5, 2017
Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR reportJeffrey R Schriber, Parameswaran N Hari, Kwang Woo Ahn, et al.Journal of Hematology & Oncology|August 22, 2020
Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic riskKatja Weisel, Andrew Spencer, Suzanne Lentzsch, et al.Pageof 5